WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 47'0301 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 42'7251 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 11'299  11'226  11'153  11'080  11'005  10'268  9'978  9'856 
Births 130  130  129  129  129  114  119  119 
Surviving infants 130  129  129  129  128  114  118  118 
Pop. less than 5 years 653  652  652  651  646  574  594  604 
Pop. less than 15 years 1'915  1'896  1'880  1'865  1'850  1'803  1'801  1'972 
Female 15-49 years 2'509  2'516  2'521  2'524  2'526  2'464  2'445  2'379 

Number of reported cases

(Click for retrospective incidence data for Belgium)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  47  70  39  109  576 
Mumps
ChartChart
  119  228  4'573  2'687  15 
Pertussis
ChartChart
  1'203  1'501  1'142  548  103 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Belgium)
Vaccine year result method % card seen                                                
BCG         
DTP1          99*  99*  99*  99*  99*  97 
DTP3          99  99  99  99  98  95  93 
DTP4          93  92  92  92  93 
IPV1          99*  99* 
HepB_BD         
HepB3          98  98  98  98  97  60 
Hib3          98  98  98  98  98  86 
JapEnc         
MCV1          96  96  96  96  95  82  85 
MCV2          85  85  85  85  83 
PCV1          98  98  98  98 
PCV3          94  93  93  93 
Pol3          99  99  99  99  98  96  95 
Rota1          91  89  89  89 
RotaC          88  86  86  86 
Rubella1          96  96  96  96  95 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Belgium)
DTP1
ChartChart
  99  99  99  99  99  97  97  98 
DTP3
ChartChart
  99  99  99  99  98  95  93  95 
HepB3
ChartChart
  98  98  98  98  97  60 
HepB_BD
ChartChart
 
Hib3
ChartChart
  98  98  98  98  98  86 
MCV1
ChartChart
  96  96  96  96  95  82  85 
MCV2
ChartChart
  85  85  85  85  83 
PCV3
ChartChart
  94  93  93  93 
Pol3
ChartChart
  99  99  99  99  98  96  95  99 
RCV1
ChartChart
  96  96  96  96  95  82  85 
RotaC
ChartChart
  88  86  86  86 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 8, 12, 16 weeks; 15 months; Yes
DTaPIPV 5-7 years; Yes or 5-6 years
HPV 10-13 years; +6 months; Yes
IPV 8, 16 weeks; 15 months; Yes if hexavalent not possible
Influenza_Adult Yes elderly, pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12 months; 10-13 years; Yes
MenC_conj 15 months; Yes
Pneumo_conj 8, 16 weeks; 12 months; Yes
Rotavirus 8, 12, 16 weeks; Yes 3rd dose depend on vaccine presentation
Td 14 years; +10 years; No and during pregnancy
Tdap 15-16 years; No

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2012-2020      2009-2010  2009-2010  2009-2010 
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 43  43  43  43  43  43  43 
Nº districts with DTP3 coverage >=80% number              
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number              
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes  NA  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.